Tirzepatide is producing the most significant weight loss results in the history of pharmaceutical treatment for obesity. In clinical trials, patients lost an average of 20 to 22.5 percent of total body weight, or roughly 48 to 54 pounds for a 240-pound patient. It is also the GLP-1 patients ask for by name, and a brand can offer it two ways: as branded Zepbound, or as a compounded formulation when a licensed provider determines a patient-specific need.
This guide walks through exactly how to build a tirzepatide telehealth brand: what the opportunity looks like, why tirzepatide outperforms semaglutide for most patients, how the business model works, and how to launch under your own brand in about 30 days, or in about 7 days if you already have your own website and LegitScript certification.
Why Tirzepatide Is the Biggest GLP-1 Opportunity in 2026
Two factors make tirzepatide the leading GLP-1 opportunity right now:
1. Superior clinical results. The SURMOUNT-1 trial published in the New England Journal of Medicine showed tirzepatide at the highest dose (15 mg) produced 22.5 percent mean body weight reduction over 72 weeks. For a 250-pound patient, that is 56 pounds of weight loss. These results are unmatched by any weight loss medication in the FDA approval history.
2. Two compliant ways to offer it. Branded Zepbound is FDA-approved for chronic weight management. Compounded tirzepatide is still available from licensed 503A pharmacies when a provider documents that an individual patient needs something the brand-name product doesn’t offer. The FDA declared the tirzepatide shortage resolved in December 2024, so compounded tirzepatide can no longer be a routine copy of Zepbound or Mounjaro. The GLP-1 compounding regulations guide has the full timeline.
The Dual-Mechanism Advantage
Where semaglutide works on one receptor (GLP-1), tirzepatide works on two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
The GIP receptor appears to amplify the GLP-1 response. It improves insulin sensitivity, modulates appetite at both the gut and brain level, and enhances fat metabolism through brown adipose tissue activation. The combined effect produces faster results, stronger weight loss, and often better tolerability than GLP-1 agonists alone. This is particularly true at lower doses, where gastrointestinal side effects are manageable.
For patients who tried semaglutide with limited results or struggled with side effects, tirzepatide is often the more effective option. This creates a natural upgrade or alternative conversion story for operators.
Building a Tirzepatide Brand: The Business Model
The model is the same as any GLP-1 telehealth brand:
- Patients pay a monthly subscription for provider-supervised tirzepatide therapy
- A licensed provider evaluates each patient and decides what to prescribe: branded Zepbound, or compounded tirzepatide when the patient has a documented need the brand-name product doesn’t meet
- A licensed pharmacy fulfills and ships the medication (a 503A compounding pharmacy for compounded prescriptions)
- You own the brand, the marketing, and the patient relationship
Illustrative economics for compounded prescriptions:
- Revenue per patient: $249 to $399 per month
- Platform and pharmacy cost: $90 to $130 per patient per month
- Operator net: $120 to $175 per patient per month
- Patient lifetime: 8 to 18 months
At 200 active patients on those numbers, a tirzepatide brand generates $24,000 to $35,000 per month for the operator. Don’t forecast as if every patient will be compounded: compounded tirzepatide goes only to patients with a documented clinical need, and the rest can be offered branded Zepbound at a price you set. Model both.
Niches That Work Well for Tirzepatide Brands
The mass-market GLP-1 brands have high customer acquisition costs because they target everyone. Niche brands win by serving specific audiences with higher trust and lower acquisition costs:
Weight loss coaches with existing audiences. If you already coach clients on nutrition and fitness, a provider-supervised tirzepatide program is a natural premium upsell. Your existing trust means a $30 to $60 patient acquisition cost instead of $250 to $500 for cold audiences.
Postpartum wellness brands. Women who gained significant weight during pregnancy and are struggling to lose it are highly motivated buyers and have strong communities around postpartum recovery.
40-plus women’s health brands. Perimenopausal and menopausal weight gain is a specific, underserved pain point. A tirzepatide brand focused on hormonal weight management for women over 40 has clear differentiation and a large addressable audience.
Medical professional communities. Nurses, physical therapists, and other healthcare workers are often knowledgeable about GLP-1 therapy and interested in the clinical side. A brand specifically for healthcare workers can command premium pricing.
Compliance Considerations
Launching a tirzepatide brand requires attention to three areas:
FDA compounding compliance. Compounded tirzepatide must be made from FDA-compliant bulk drug substance at a licensed 503A pharmacy, for an individual patient whose prescriber documents a significant difference from Zepbound or Mounjaro. On Karpa, independent licensed providers make and document that decision and LegitScript-certified 503A pharmacy partners fill the prescription, but operators should understand the structure.
FTC weight loss advertising rules. The FTC requires that all weight loss claims in advertising be truthful, substantiated, and not make specific outcome guarantees that are not typical for the general consumer. Testimonials must disclose if results are atypical. See the FTC’s guidance at ftc.gov.
State telehealth prescribing rules. The licensed prescribers in your platform’s provider network must comply with the prescribing and telehealth practice rules of each patient’s state. A 50-state provider network handles this by keeping credentialed physicians in every jurisdiction.
How to Launch
- Apply to partner with a turnkey telehealth platform
- Select your program (tirzepatide, or tirzepatide plus additional metabolic support)
- Set your pricing and brand configuration
- Complete onboarding
- Launch marketing and begin accepting patients
On Karpa, tirzepatide brand partners go live in about 30 days when Karpa builds the website, or in about 7 days if they already have their own website and LegitScript certification.
Build on Compliance, Not a Loophole
The shortage era that let pharmacies compound routine copies of Zepbound is over, and the FDA is enforcing the rules that replaced it. Tirzepatide brands that last are built on patient-specific prescribing, licensed 503A pharmacies, honest marketing (compounded tirzepatide is not FDA-approved and is not the same drug as Zepbound), and a branded option for patients who want one. Operators who build a patient base and brand equity on that footing now are in a far stronger position than those who wait.
Book a call with Karpa Health to discuss launching a tirzepatide brand under your name.
For more context on closely related topics, read how to start a GLP-1 telehealth brand, semaglutide telehealth brand launch guide. To see how the platforms themselves compare before you commit, read the best GLP-1 and peptide platforms roundup.
